Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1976 1
2000 1
2001 2
2002 3
2003 1
2004 4
2006 1
2007 3
2008 4
2009 2
2010 2
2011 3
2012 4
2013 1
2014 4
2015 4
2016 8
2017 5
2018 8
2019 5
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. ...Oncolytic viral therapy for glioma remains promising and will undoubtedly impact the future of patient care....
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. .
Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW, Brown MC, Sacco MT, Gromeier M. Walton RW, et al. J Virol. 2018 Sep 12;92(19):e00879-18. doi: 10.1128/JVI.00879-18. Print 2018 Oct 1. J Virol. 2018. PMID: 29997212 Free PMC article.
We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated type 1 (Sabin) poliovirus vaccine carrying a heterologous internal ribosomal entry site (IRES) of human rhinovirus type 2 (HRV2). ...This has …
We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated type 1 ( …
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Desjardins A, et al. N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26. N Engl J Med. 2018. PMID: 29943666 Free PMC article. Clinical Trial.
PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment. ...
PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major componen …
Recombinant Poliovirus for Cancer Immunotherapy.
Gromeier M, Nair SK. Gromeier M, et al. Annu Rev Med. 2018 Jan 29;69:289-299. doi: 10.1146/annurev-med-050715-104655. Annu Rev Med. 2018. PMID: 29414253 Free PMC article. Review.
"Oncolytic" viruses, naturally existing or genetically engineered viral agents with cell type-specific propagation in malignant cells, were ostensibly conceived for their tumor cytotoxic properties. ...In this review, we explain the mechanisms of recombinant nonpathogenic …
"Oncolytic" viruses, naturally existing or genetically engineered viral agents with cell type-specific propagation in malignant cells …
Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
Brown MC, Gromeier M. Brown MC, et al. Discov Med. 2015 May;19(106):359-65. Discov Med. 2015. PMID: 26105699 Free PMC article. Review.
A natural ability to recruit effector responses makes tumor-targeting ('oncolytic') viruses attractive as immunotherapy vehicles. ...We are pioneering oncolytic immunotherapy based on poliovirus, which has no specific mechanism to interfere with host immune a …
A natural ability to recruit effector responses makes tumor-targeting ('oncolytic') viruses attractive as immunotherapy vehicles. ... …
Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
Brown MC, Gromeier M. Brown MC, et al. Curr Opin Virol. 2015 Aug;13:81-5. doi: 10.1016/j.coviro.2015.05.007. Epub 2015 Jun 12. Curr Opin Virol. 2015. PMID: 26083317 Free PMC article. Review.
An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targeted inflammatory cancer cell killing; a principle that is showing promise in clinical trials for recurrent glioblastoma (GBM). ...
An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targ …
The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.
Denniston E, Crewdson H, Rucinsky N, Stegman A, Remenar D, Moio K, Clark B, Higginbotham A, Keffer R, Brammer S, Horzempa J. Denniston E, et al. Am J Virol. 2016;5(1):1-7. doi: 10.3844/ajvsp.2016.1.7. Epub 2016 Mar 3. Am J Virol. 2016. PMID: 28203321 Free PMC article.
Recently, a recombinant Poliovirus-Rhinovirus Chimera (PVSRIPO) has shown promise for the treatment of glioblastoma in clinical trials as well as other cancer types in animal models. In this literature review, we discuss the use of PVSRIPO as an oncolytic virotherap …
Recently, a recombinant Poliovirus-Rhinovirus Chimera (PVSRIPO) has shown promise for the treatment of glioblastoma in clinical trial …
Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells.
Sosnovtseva AO, Zheltukhin AO, Lipatova AV, Chumakov PM, Chekhonin VP. Sosnovtseva AO, et al. Bull Exp Biol Med. 2019 May;167(1):111-115. doi: 10.1007/s10517-019-04472-6. Epub 2019 Jun 8. Bull Exp Biol Med. 2019. PMID: 31177454
Rat glioma cell line C6 expressing human poliovirus receptor (PVR) and susceptible to polioviruses (C6-PVR-BFP) was used to produce a clone with knockout of IFNα/β (Ifnar1) receptor subunit 1 gene (Ifnar1). ...Using the model of subcutaneous tumor xenografts, we dem …
Rat glioma cell line C6 expressing human poliovirus receptor (PVR) and susceptible to polioviruses (C6-PVR-BFP) was used to pr …
Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.
Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M. Thompson EM, et al. J Neuropathol Exp Neurol. 2018 Aug 1;77(8):696-702. doi: 10.1093/jnen/nly045. J Neuropathol Exp Neurol. 2018. PMID: 29878245 Free PMC article.
Poliovirus oncolytic immunotherapy is a putatively novel approach to treat pediatric brain tumors. This work sought to determine expression of the poliovirus receptor (PVR), CD155, in low-grade and malignant pediatric brain tumors and its ability to infect, p
Poliovirus oncolytic immunotherapy is a putatively novel approach to treat pediatric brain tumors. This work sought to determi
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.
Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Brown MC, et al. Sci Transl Med. 2017 Sep 20;9(408):eaan4220. doi: 10.1126/scitranslmed.aan4220. Sci Transl Med. 2017. PMID: 28931654 Free PMC article.
This study defines the adjuvant and cancer immunotherapy potential of the recombinant poliovirus/rhinovirus chimera PVSRIPO. ...
This study defines the adjuvant and cancer immunotherapy potential of the recombinant poliovirus/rhinovirus chimera PVSRIPO. ...
63 results
Jump to page
Feedback